Modafinil Derivatives for Vascular Disease Treatment via cAMP Elevation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vascular diseases and KCa3.1 channel-mediated diseases lack effective oral cAMP-dependent medications, and existing KCa3.1 channel inhibitors have limitations in efficacy and side effects, particularly in increasing intracellular cAMP levels to relax blood vessels and inhibit KCa3.1 currents.
Innovation Solution
Modafinil and its derivatives increase intracellular cAMP levels, leading to vascular smooth muscle relaxation and KCa3.1 current inhibition through phosphorylation of the KCa3.1 channel protein, providing a novel pharmaceutical composition for treating vascular diseases and KCa3.1 channel-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing KCa3.1 channel inhibitors are used to treat vascular diseases, then KCa3.1 currents are inhibited, but they have limitations in efficacy and cause side effects like elevated blood pressure
Solution Approach 1:
The patent changes the molecular structure parameters of modafinil to create derivatives with optimized properties. The derivatives maintain the core modafinil structure but modify specific functional groups to enhance KCa3.1 channel inhibition efficacy while reducing side effects like blood pressure elevation, as demonstrated by the structure-activity relationship studies in the patent
Solution Approach 2:
The patent creates simplified copies of complex natural compounds. Instead of using complex natural KCa3.1 channel inhibitors, the patent develops modafinil derivatives that copy the essential pharmacophore features while having simpler molecular structures, making them easier to synthesize and potentially more selective for the desired therapeutic effect
2Ease of operation
If iloprost is used to treat pulmonary hypertension, then blood vessels are relaxed through cAMP increase, but it is only available in inhaled or intravenous form, not oral form
Solution Approach 1:
The patent uses modafinil, a commercially available drug with known pharmacokinetic properties, as a starting point. By leveraging the existing oral bioavailability of modafinil and its metabolites, the patent creates orally available cAMP-elevating compounds without requiring complex delivery systems, making the treatment more accessible and convenient for patients
Solution Approach 2:
The patent discovers that modafinil and its derivatives have multiple functions: they increase intracellular cAMP levels, relax vascular smooth muscle, inhibit KCa3.1 channels, and are orally bioavailable. This multi-functionality allows a single oral medication to address multiple aspects of vascular disease treatment that previously required multiple medications or invasive administration routes
3Ease of manufacture
If modafinil derivatives are developed with simpler structure, then synthesis becomes easier, but maintaining efficacy and selectivity becomes more challenging
Solution Approach 1:
The patent segments the modafinil molecule into functional regions: the core benzhydryl structure, the sulfinyl group, and the acetamide side chain. By systematically modifying each segment while keeping others constant, the patent identifies which structural elements are critical for KCa3.1 channel binding and cAMP elevation, allowing optimization of synthesis routes while maintaining pharmacological activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Modafinil and its derivatives effectively relax blood vessels and inhibit KCa3.1 currents, offering a potential treatment for vascular diseases such as hypertension and KCa3.1 channel-mediated conditions like atherosclerosis without significant side effects like elevated blood pressure, similar to existing treatments like iloprost but with a simpler structure for easier synthesis.
Implementation Method 1
Modafinil and its derivatives increase intracellular cAMP levels, leading to vascular smooth muscle relaxation and KCa3.1 current inhibition through phosphorylation of the KCa3.1 channel protein
Implementation Method 2
Modafinil and its derivatives increase intracellular cAMP levels, leading to vascular smooth muscle relaxation and KCa3.1 current inhibition through phosphorylation of the KCa3.1 channel protein
Data Source
AI summary
The present invention relates to modafinil or derivatives thereof as a medicine for the treatment of vascular diseases or KCa3.1 channel (Ca activated K channel) mediated diseases and a novel use of the same. More specifically, the present invention relates to a pharmaceutical composition for the prevention or treatment of vascular diseases or KCa3.1 channel-mediated diseases comprising modafinil or a derivative of modafinil, or pharmaceutically acceptable salts thereof which relax blood vessels and inhibit KCa3.1 channel currents by increasing intracellular cAMP, a method for treating vascular diseases or KCa3.1 channel-mediated diseases using the composition and a health functional food composition for the prevention or improvement of vascular diseases or the KCa3.1 channel-mediated diseases comprising modafinil or a modafinil derivative compound, or sitologically acceptable salts thereof.